Adaptimmune Therapeutics Plc Stock Fundamentals
| ADAP Stock | USD 0.72 0.01 1.37% |
Adaptimmune Therapeutics Plc fundamentals help investors to digest information that contributes to Adaptimmune Therapeutics' financial success or failures. It also enables traders to predict the movement of Adaptimmune Stock. The fundamental analysis module provides a way to measure Adaptimmune Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adaptimmune Therapeutics stock.
At this time, Adaptimmune Therapeutics' Non Operating Income Net Other is relatively stable compared to the past year. Adaptimmune | Select Account or Indicator |
Adaptimmune Therapeutics Plc Company Current Valuation Analysis
Adaptimmune Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Adaptimmune Therapeutics Current Valuation | 73.92 M |
Most of Adaptimmune Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adaptimmune Therapeutics Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adaptimmune Current Valuation Historical Pattern
Today, most investors in Adaptimmune Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adaptimmune Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Adaptimmune Therapeutics current valuation as a starting point in their analysis.
Adaptimmune Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Adaptimmune Therapeutics Plc has a Current Valuation of 73.92 M. This is 99.49% lower than that of the Biotechnology sector and 98.41% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.56% higher than that of the company.
Adaptimmune Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Adaptimmune Therapeutics's current stock value. Our valuation model uses many indicators to compare Adaptimmune Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adaptimmune Therapeutics competition to find correlations between indicators driving Adaptimmune Therapeutics's intrinsic value. More Info.Adaptimmune Therapeutics Plc is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Adaptimmune Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adaptimmune Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Adaptimmune Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adaptimmune Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adaptimmune Therapeutics could also be used in its relative valuation, which is a method of valuing Adaptimmune Therapeutics by comparing valuation metrics of similar companies.Adaptimmune Therapeutics is currently under evaluation in current valuation category among its peers.
Adaptimmune Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adaptimmune Therapeutics from analyzing Adaptimmune Therapeutics' financial statements. These drivers represent accounts that assess Adaptimmune Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adaptimmune Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 126.0M | 767.9M | 584.3M | 235.4M | 159.5M | 151.5M | |
| Enterprise Value | 101.0M | 734.7M | 459.8M | 150.4M | 40.7M | 38.7M |
Adaptimmune Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | 0.54 % | ||||
| Current Valuation | 73.92 M | ||||
| Shares Outstanding | 255.88 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 60.26 % | ||||
| Number Of Shares Shorted | 6.91 M | ||||
| Price To Earning | (7.73) X | ||||
| Price To Book | 2.32 X | ||||
| Price To Sales | 1.31 X | ||||
| Revenue | 60.28 M | ||||
| Gross Profit | (100.58 M) | ||||
| EBITDA | (128.2 M) | ||||
| Net Income | (113.87 M) | ||||
| Cash And Equivalents | 199.67 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 25.23 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 4.00 X | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (140.88 M) | ||||
| Short Ratio | 4.71 X | ||||
| Earnings Per Share | (0.17) X | ||||
| Price To Earnings To Growth | 0.11 X | ||||
| Target Price | 2.27 | ||||
| Number Of Employees | 449 | ||||
| Beta | 2.25 | ||||
| Market Capitalization | 185.52 M | ||||
| Total Asset | 282.62 M | ||||
| Retained Earnings | (1.02 B) | ||||
| Working Capital | 134.76 M | ||||
| Current Asset | 199.54 M | ||||
| Current Liabilities | 22.66 M | ||||
| Net Asset | 282.62 M |
About Adaptimmune Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptimmune Therapeutics Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptimmune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptimmune Therapeutics Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 29 M | 21 M | |
| Cost Of Revenue | 9.9 M | 9.4 M | |
| Total Revenue | 60.3 M | 63.3 M | |
| Stock Based Compensation To Revenue | 0.20 | 0.19 | |
| Sales General And Administrative To Revenue | 1.19 | 1.13 | |
| Research And Ddevelopement To Revenue | 2.10 | 1.99 | |
| Capex To Revenue | 0.08 | 0.08 | |
| Revenue Per Share | 0.30 | 0.23 | |
| Ebit Per Revenue | (2.29) | (2.40) |
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
Moving against Adaptimmune Stock
| 0.84 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.83 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.82 | GILD | Gilead Sciences | PairCorr |
| 0.76 | BHC | Bausch Health Companies | PairCorr |
| 0.74 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.